These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25521356)

  • 1. Genotype and risk of major bleeding during warfarin treatment.
    Kawai VK; Cunningham A; Vear SI; Van Driest SL; Oginni A; Xu H; Jiang M; Li C; Denny JC; Shaffer C; Bowton E; Gage BF; Ray WA; Roden DM; Stein CM
    Pharmacogenomics; 2014 Dec; 15(16):1973-83. PubMed ID: 25521356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
    Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
    Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.
    Hart R; Veenstra DL; Boudreau DM; Roth JA
    Am J Med; 2017 Feb; 130(2):222-228. PubMed ID: 27593608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
    Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Paré G; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Yusuf S; Wadelius M
    Pharmacogenomics; 2016 Aug; 17(13):1425-39. PubMed ID: 27488176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
    Kim KA; Song WG; Lee HM; Joo HJ; Park JY
    Mol Biol Rep; 2014 Nov; 41(11):7305-12. PubMed ID: 25069408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
    Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
    Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
    Zhang S; Zhao M; Zhong S; Niu J; Zhou L; Zhu B; Su H; Cao W; Xing Q; Yan H; Han X; Fu Q; Li Q; Chen L; Yang F; Zhang N; Wu H; He L; Qin S
    Pharmacogenet Genomics; 2024 Jun; 34(4):105-116. PubMed ID: 38470454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.